CHESS ROBERT
Known title: DirectorCIK: 0001227886
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Twist Bioscience highlighted in AI biofoundry and analyst upgrades. Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.
Transaction History
| NKTR | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 18,417 | $2.0M | 8/7/2026 | View on chart |
| TWST | ▲ Buy | Option Exercise | 18,417 | $219K | 8/7/2026 | View on chart |
| TWST | ▲ Buy | Option Exercise | 10,000 | $119K | 3/17/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 10,000 | $470K | 3/17/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 2,184 | $105K | 2/13/2026 | View on chart |
| TWST | ▲ Buy | Grant | 5,095 | $0 | 2/5/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 2,940 | $156K | 2/7/2025 | View on chart |
| TWST | ▲ Buy | Grant | 4,472 | $0 | 2/5/2025 | View on chart |
| TWST | ▼ Sell | Open Market | 5,000 | $250K | 1/7/2025 | View on chart |
| TWST | ▲ Buy | Option Exercise | 3,504 | $31K | 12/5/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 2,795 | $145K | 12/5/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 709 | $37K | 12/5/2024 | View on chart |
| TWST | ▲ Buy | Option Exercise | 3,600 | $32K | 11/11/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 2,324 | $109K | 11/11/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 1,276 | $61K | 11/11/2024 | View on chart |
| NKTR | ▼ Sell | Open Market | 19,500 | $23K | 6/14/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 4,110 | $144K | 2/8/2024 | View on chart |
| TWST | ▲ Buy | Grant | 5,815 | $0 | 2/6/2024 | View on chart |
| TWST | ▲ Buy | Grant | 8,212 | $0 | 2/7/2023 | View on chart |
| NKTR | ▼ Sell | Open Market | 10,200 | $7K | 9/22/2022 | View on chart |
| NKTR | ▼ Sell | Open Market | 5,100 | $16K | 9/22/2022 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 | View on chart |
| TWST | ▲ Buy | Grant | 3,491 | $0 | 2/8/2022 | View on chart |
| TWST | ▼ Sell | Open Market | 253 | $15K | 2/4/2022 | View on chart |
| TWST | ▼ Sell | Open Market | 4,000 | $481K | 11/1/2021 | View on chart |
| TWST | ▼ Sell | Open Market | 3,700 | $445K | 10/21/2021 | View on chart |
| TWST | ▼ Sell | Open Market | 300 | $36K | 10/19/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 4,600 | $83K | 9/22/2021 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 | View on chart |
| TWST | ▼ Sell | Open Market | 4,000 | $481K | 9/10/2021 | View on chart |
| NKTR | ▲ Buy | Option Exercise | 10,279 | $142K | 9/9/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 10,279 | $165K | 9/9/2021 | View on chart |
| NKTR | ▲ Buy | Option Exercise | 8,000 | $110K | 9/8/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 8,000 | $128K | 9/8/2021 | View on chart |
| NKTR | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 | View on chart |
| NKTR | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 | View on chart |
| NKTR | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 | View on chart |
| NKTR | ▼ Sell | Gift | 6,300 | $0 | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus
Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.